APPROACH
DRI Capital’s strengths as counterparty in royalty monetization transactions include its:
- Relationship Oriented Approach
- Breadth of Knowledge
- Certainty of Deal Execution
- Access to Capital
PORTFOLIO
As a result of these transactions, DRI Capital, through its managed funds, owns royalties on some of the best-selling biopharmaceutical products in the world including:
DRI CAPITAL
100 King St. West, Suite 7250
PO Box 62
Toronto, ON M5X 1B1
T: 416-863-1865
info@dricapital.com
Investor Relations:
driinvestorrelations@dricapital.com
APPROACH
DRI Capital’s strengths as counterparty in royalty monetization transactions include its:
- Relationship Oriented Approach
- Breadth of Knowledge
- Certainty of Deal Execution
- Access to Capital
PORTFOLIO
As a result of these transactions, DRI Capital, through its managed funds, owns royalties on some of the best-selling biopharmaceutical products in the world including:
DRI CAPITAL
100 King St. West, Suite 7250
PO Box 62
Toronto, ON M5X 1B1
T: 416-863-1865
info@dricapital.com
Investor Relations:
driinvestorrelations@dricapital.com
